← All indications
Philadelphia Chromosome
An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).
Drugs by status
Approved for this indication (1)
Organizations
Organization Involved with Phase 4 Indications (7)
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (37)
- ADC Therapeutics SARL
- Incyte
- AbbVie
- Takeda
- Amgen
- Pharmacyclics
- Ariad Pharmaceuticals
- Hengrui Therapeutics, Inc.
- University of Roma La Sapienza
- Renato Melaragno
- Azienda Ospedaliera San Gerardo di Monza
- Cancer and Leukemia Group B (CALGB)
- Centre Leon Berard
- University of Washington
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Guangxi Medical University
- Johns Hopkins University
- Southwest Oncology Group
- University of Versailles
- Mayo Clinic
- Dutch Childhood Oncology Group
- University of California, Davis
- University of Ulsan
- Azienda ULSS 12 Veneziana
- The University of Hong Kong
- City of Hope National Medical Center
- University of Nantes
- Hospital Santa Marcelina, Sao Paulo, Brasil
- J. W. Goethe University
- Erasmus University Rotterdam
- +7 more
Organization Involved with Phase 1 Indications (13)
Organization Involved with Other Experimental Indications (1)